Facial Injectable Market

Market Overview

The global facial injectable market size was worth USD 14.5 billion in 2021. It is expected to reach USD 31 billion by 2030, growing at a CAGR of 8.8% during the forecast period (2022–2030).

Facial injectables contribute to the skin renewal on the face by improving the lips, reducing wrinkles, and enhancing scar depression. Various products are available on the global market, including natural fillers made of collagen, hyaluronic Acid, and calcium hydroxylapatite. With relatively few adverse side effects, hyaluronic Acid is an injectable chemical that enhances skin hydration, skin health, and UV protection.

Increasing awareness about esthetic procedures among consumers and the growing geriatric population worldwide are anticipated to drive the market. Furthermore, the shift in trend from invasive to minimally invasive procedures and advancements in facial rejuvenation is expected to support market growth over the forecast period. Advances in facial rejuvenation procedures with changes in products, practices, and patient demographics are helping dermatologists or physicians treat multiple facial areas & customize treatments for individual patients, and facilitate the use of a combination of products to obtain better outcomes. These factors propelled the market growth over the forecast period.

Market Dynamics

Drivers: Increasing Beauty Consciousness Among People

Growing insurance schemes for esthetic and cosmetic procedures have contributed to the improving awareness and acceptance of facial injectables, thereby propelling the market. For instance, the UK-based insurance company, Hamilton Fraser, is dedicated to providing insurance for esthetic procedures like laser treatments, dermal fillers, chemical peels, and botulinum toxin. As per a survey conducted in the UK, women opted for esthetic procedures due to low self-esteem, low self-rated physical attractiveness, and low life satisfaction.

The number of men considering these procedures is also significant. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2019, around 841,735 botulinum toxin injectable procedures were performed on men globally. Owing to the rising gender equality agenda and millennials with a more liberal mindset, the facial injectable market is expected to grow during the forecast period.

Drivers: Shifting Consumer Preferences for Minimally Invasive Procedures

A shift from invasive to minimally invasive procedures is expected to fuel the market growth over the forecast period. According to ISAPS, 13,618,735 noninvasive procedures were performed globally in 2019, out of which 3,982,749 were performed in the US. More people are opting for permanent methods such as fillers, fat grafting, and lip advancement. The most popular procedures are fillers, as the risk associated with this treatment is very low. Fillers such as hyaluronic acid and poly-L lactic acid are readily accepted by the body, leading to minimal side effects and allergic reactions. ISAPS also suggests that botulinum toxin filler, hyaluronic acid filler, non-surgical fat reduction, and photo rejuvenation are some standard, in-demand, noninvasive esthetic procedures.

Minimally invasive procedures offer fewer incisions, shorter hospital stays, quick outpatient services, rapid wound healing, lesser pain, and a lower risk of complications than invasive surgeries. Therefore, the demand for facial injectables will increase during the forecast period. Moreover, many dermatologists believe that COVID-19 may act as a springboard to improving patient footfall post-pandemic drastically. According to a survey of 1,000 American women in 2020 by the American Society of Plastic Surgeons, 11% of participants indicated that they are more inclined to opt for minimally invasive post-pandemic procedures than before COVID-19. Even during the pandemic, Botox and soft tissue fillers remained the most popular minimally invasive procedure in the US.

Increasing disposable income among consumers

In addition to a rise in aesthetic attractiveness consciousness, there has been a considerable increase in disposable money globally. So, as more people opt to enhance their physical features, attitudes around cosmetic surgery have changed. Due to its reputation for safety and short to no recovery times, minimally invasive procedures like face injectables are becoming increasingly popular. Among the injectables for the face that are offered for sale are neurotoxins like botulinum toxin and dermal fillers like hyaluronic acid and calcium hydroxylapatite.

Launch of New Products to Support Market Growth

The urge for more excellent aesthetic appearance and the development of new fillers have been two major factors driving the total demand for filler operations throughout the years. Improved and more effective products have been introduced due to this trend in R&D initiatives for developing novel fillers. The increased use of these fillers is primarily due to introduction of new products with better aesthetic results.
JUVÉDERM VOLUX, Allergan's most recent addition to its line of facial fillers, was introduced in April 2020. It was created for people who want a more defined chin and jawline. Such product launches have introduced new application indications as well as novel items to a larger population.

Restraint: Adverse Effects of Facial Injectables

Currently, only one product of botulinum toxin-B and a few products of botulinum toxin-A are commercially available in the market. Commercially available products, such as Botox and Dysport, are effective for removing moderate to severe glabellar lines. However, adverse effects such as rash, allergic reactions, back & neck pain, nausea, and shortness of breath, which can be temporary in most cases and vary from person to person, may limit the adoption of Botox in esthetic as therapeutic applications.

Another factor that may restrain the market growth is limited reimbursement policies, as esthetic procedures such as reducing wrinkles and removing excess skin are not covered under private and government insurance plans. However, most countries cover the therapeutic use of botulinum toxin under reimbursement plans. In June 2019, Allergan announced FDA clearance of the company's supplemental biologics application for BOTOX to treat upper limb spasticity in children. Side-effects of other facial injectables, such as hyaluronic acid, include legal & regulatory issues and safety concerns, which are anticipated to impede the market growth.

Growth Opportunities in Global Facial Injectable Market 

• Growing Population Aged 25–65 Years

Wrinkles and sagging skin from lack of face elasticity, dark spots, and other aging symptoms start to show up between the ages of 25 and 30, and they grow more evident between the ages of 30 and 65. Therefore, a large population susceptible to various signs of aging is boosting the demand for facial injectable medicine globally. According to World Population Prospects 2019, in 2050, one out of six people will be aged 65 globally, increasing from one in 11 in 2019. According to the estimates published by United Nations, there were 703 million people above the age of 65 around the world in 2019, and the number of older adults is estimated to double by 2050.

According to the United Nations Population Fund (UNFPA) State of World Population 2019, released in April 2020, India's population in 2019 was 1.36 billion, increasing from 942.2 million in 1994, and 6% of India's population was aged 65 and above. Between 2019 and 2050, nine out of the ten countries with the most significant percentage point increase in the share of elderly persons are estimated to be in Eastern and Southeastern Asia. Consequently, the population prone to experiencing signs of aging is expected to grow during the forecast period.

Regional Analysis

Based on region, the global facial injectable market share is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Which Region Commands the Maximum Market Share Globally?

North America held over 41% share in the global facial injectable market analysis in 2021 due to increased spending on aesthetic procedures. It is expected to grow at a CAGR of 9.18% during the forecast period. A large geriatric population base in the US and Canada is anticipated to propel the demand for injectables over the forecast period. 

Asia-Pacific is anticipated to be the fastest-growing region over the forecast period. China, India, and Japan are the developing economies in this region and have great potential for growth in the facial injectable market. This can be attributed to the growing medical tourism industry, especially in these countries. A large number of surgical procedures performed in South Korea, Japan, and China each year are primarily driving the market growth in this region. Many esthetic procedures can be attributed to the easy availability of advanced techniques and cost-effective treatment options. Additionally, a large geriatric population is anticipated to be a high-impact rendering driver for this region. 

Europe is the second-largest region and is expected to grow at a CAGR of 8.6% during the forecast period, accounting for USD 7,275 million. Germany is one of the significant countries spearheading the facial injectable market. Factors such as the increased popularity of cosmetic procedures, technological advancements, and beauty consciousness are among the factors driving the market growth. Furthermore, the rising urban population, novel product approvals, promotions in noninvasive procedures, and availability of skilled professionals are other factors leading to the market growth.

According to European Union Medical Device Regulation, all dermal fillers are classified under medical devices. European Notified Bodies must audit these fillers regularly and rigorously to ensure that international standards and Health Products Regulatory Authority (HPRA) regulations are complied with. In addition, the presence of manufacturing units of key market players such as Merz Pharma, specializing in the manufacturing of hyaluronic acid-based fillers, ensures the availability of sophisticated & technologically advanced products in the country, thereby fueling the market growth.

Segmental Analysis

The global facial injectable market share is segmented by product, application, and region. 

Based on product, the global facial injectable market growth is segmented into Collagen, Hyaluronic Acid, Botulinum Toxin Type A, Calcium Hydroxylapatite, and Polymer Fillers.

• By Product

Botulinum Toxin Type A dominates the market and is expected to grow at a CAGR of 9.2% during the forecast period. This can be accredited to the increase in applications of BoNTA in cosmetic (esthetic) procedures, improvements in facial appearance, and its effectiveness in reducing signs of aging. Furthermore, BoNTA has therapeutic applications in treating benign essential blepharospasm, Meige's syndrome, strabismus or crossed eyes, Hemifacial Spasm (HFS), Oromandibular Dystonia (OMD), and focal hyperhidrosis.

Botox is a minimally invasive procedure with less procedure time, provides high patient comfort, and delivers quicker results. It was also observed that in 2019, around 473,354 botulinum toxin filler procedures were performed on men in the US. This indicates that demand for the procedure is rapidly increasing among men. This procedure accounts for 46.1% of the top five noninvasive esthetic procedures globally, showing high demand, which is expected to boost the market growth.

Hyaluronic Acid is the fastest-growing segment. Cosmetic-grade HA has a low molecular weight that makes it easier for the product to penetrate deep into the epidermis, aiding in water retention in the cells and releasing antioxidants that slow down the aging process. In addition to acting as a moisturizer, H.A. is used to treat burns, skin ulcers, and wounds. H.A. is also used as a lip filler in plastic surgery. According to the International Society of Aesthetic Plastic Surgery, around 4,315,859 procedures of hyaluronic dermal injections were performed globally in 2019. This procedure accounts for 31.7% of the top five noninvasive esthetic procedures performed in the country, indicating high demand for the process, which is expected to contribute to increased market growth.

Calcium Hydroxylapatite is an injectable dermal filler called calcium hydroxylapatite (CaHA) contains homogeneous CaHA microspheres encapsulated in an aqueous carboxymethylcellulose gel carrier. It is highly biocompatible with human tissue and regarded as a long-lasting but non-permanent filler.

• By Application

Based on application, the global facial injectable market forecast is segmented into Aesthetics and Therapeutics.

Due to the growing awareness about aesthetic procedures and rising disposable income, the Aesthetics segment will likely hold a significant share of 70% of the global injectable facial market. It is expected to grow at a CAGR of 9.25% during the forecast period. The use of facial Injectable for parentheses lines, wrinkles on the face, lip lines, lip augmentation, lip border restoration, perioral lines, and crow's feet lines are expected to assist in the market growth.

These procedures are also used for treating frown lines, glabellar lines, filling furrows (deep wrinkles), periorbital lines, frown lines, building facial volume, simple lines, acne scars, tear troughs, marionette lines, lipoatrophy of the face, nasolabial folds, dimpling of the chin, and mouth wrinkles, propelling the market growth. Furthermore, other aesthetic applications include surgical interventions such as plastic and facelift surgeries used to repair, restore, reconstruct, or alter the skin and reduce facial wrinkles. The facial Injectable such as botulinum toxin type A and calcium hydroxylapatite are majorly used during these procedures.

The Therapeutics segment is expected to grow swiftly over the forecast period due to a rise in the application of facial injectables in the treatment of blepharospasm, strabismus, Meige's syndrome, OMD, HFS, and focal hyperhidrosis. Botox (Allergan, Inc.) received US FDA approval for hyperhidrosis and cervical dystonia. Botox has also received support for post-stroke upper limb spasticity and chronic migraine.

Esthetic applications of fillers such as Botox are not covered under private and government insurance plans. However, most countries cover the therapeutic use of botulinum toxin under reimbursement plans. In January 2020, Ipsen announced the FDA approval of DYSPORT (abobotulinumtoxinA) for treating upper limb spasticity in children, which will help patients seeking long-lasting spasticity symptom relief. This is expected to help strengthen Ipsen's neurotoxin research.

Recent Developments

• June 2022 - Ipsen received a positive opinion in Europe for Dysport® in managing urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury. 
• May 2022 - ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and combination across different tumor types, including metastatic non-small cell lung cancer. 
• May 2022 - European Commission approved Cabometyx® as a second-line treatment for people living with radioactive iodine refractory differentiated thyroid cancer. 
• In October 2022, Galderma declared plans to increase its presence in Asia-Pacific for manufacturing and innovation.
• In December 2022, A Complete Response Letter was received from Ipsen regarding Palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva.
• In September 2022, Suneva Medical, Inc. ("Suneva" or the "Company") introduced the 30 mL version of its Amplifine Platelet Rich Plasma (PRP) gel tubes, which will give patients and practices a larger volume of PRP to address various areas of concern more effectively. Suneva is an innovative medical technology company that uses regenerative products to change the standard of care in inpatient treatments.